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Timing of pubertal stages and breast cancer risk:
the Breakthrough Generations Study
Danielle H Bodicoat1,2,6*, Minouk J Schoemaker1, Michael E Jones1, Emily McFadden1,3, James Griffin1,
Alan Ashworth4,5 and Anthony J Swerdlow1,5
Abstract
Introduction: Breast development and hormonal changes at puberty might affect breast cancer risk, but
epidemiological analyses have focussed largely on age at menarche and not at other pubertal stages.
Methods: We investigated associations between the timing of pubertal stages and breast cancer risk using data
from a cohort study of 104,931 women (Breakthrough Generations Study, UK, 2003–2013). Pubertal variables were
reported retrospectively at baseline. Breast cancer risk was analysed using Cox regression models with breast cancer
diagnosis as the outcome of interest, attained age as the underlying time variable, and adjustment for potentially
confounding variables.
Results: During follow-up (mean = 4.1 years), 1094 breast cancers (including ductal carcinoma in situ) occurred. An
increased breast cancer risk was associated with earlier thelarche (age when breast growth begins; HR [95% CI] = 1.23
[1.02, 1.48], 1 [referent] and 0.80 [0.69, 0.93] for ≤10, 11–12 and ≥13 years respectively), menarche (initiation of menses;
1.06 [0.93, 1.21], 1 [referent] and 0.78 [0.62, 0.99] for ≤12, 13–14 and ≥15 years), regular periods (0.99 [0.83, 1.18], 1
[referent] and 0.74 [0.59, 0.92] for ≤12, 13–14 and ≥15 years) and age reached adult height (1.25 [1.03, 1.52], 1
[referent] and 1.07 [0.87, 1.32] for ≤14, 15–16 and ≥17 years), and with increased time between thelarche and
menarche (0.87 [0.65, 1.15], 1 [referent], 1.14 [0.96, 1.34] and 1.27 [1.04, 1.55] for <0, 0, 1 and ≥2 years), and
shorter time between menarche and regular periods (1 [referent], 0.87 [0.73, 1.04] and 0.66 [0.50, 0.88] for 0, 1
and ≥2 years). These associations were generally similar when considered separately for premenopausal and
postmenopausal breast cancer.
Conclusions: Breast duct development may be a time of heightened susceptibility to risk of carcinogenesis, and
greater attention needs to be given to the relation of breast cancer risk to the different stages of puberty.
Introduction
Breast cancer is the most common invasive cancer among
women world-wide [1]. Timing of puberty is a potentially
important risk factor for this tumour, in terms of breast
growth and the large hormonal changes that occur around
that time. There are several stages of puberty, but epi-
demiological analyses of breast cancer risk have focussed
largely on age at menarche, perhaps because it can be
most readily recalled with reasonable accuracy [2]. The
stages of puberty, as outlined by Tanner, are thelarche (the
start of breast growth), pubarche (the start of pubic hair
growth), peak growth (an acceleration of linear growth)
and menarche (first menses) [3]. Pubertal phases relevant
to breast growth are thelarche, when growth begins, and
menarche, when it accelerates [4]; pubertal hormonal
surges are detectable by peak growth and the start of
menstruation.
Menarcheal age is a well-established breast cancer risk
factor [5], with an estimated 10% reduction in breast
cancer risk for each two-year increase in age at menar-
che [6]. Additionally, there is limited evidence indicating
higher breast cancer risk in women whose menses be-
come regular sooner, rather than later, after menarche
[7,8]. Aside from age at menarche and onset of regular
menses, the other Tanner stages have been little studied
in relation to breast cancer risk. There is weak evidence
that earlier peak growth might increase breast cancer
* Correspondence: dhm6@le.ac.uk
1Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, UK
2Diabetes Research Centre, University of Leicester, Leicester, UK
Full list of author information is available at the end of the article
© 2014 Bodicoat et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Bodicoat et al. Breast Cancer Research 2014, 16:R18
http://breast-cancer-research.com/content/16/1/R18
risk [9], but data are minimal, and there appear to have
been no studies of risk by age at thelarche.
We, therefore, investigated the associations of age at
various pubertal stages and the duration between these
stages with breast cancer risk in the Breakthrough Gen-
erations Study (BGS), a large cohort study.
Methods
Subjects
The BGS is a UK cohort study focussed on breast cancer
aetiology. It has received approval from the South Thames
Multicentre Research Ethics Committee and all partici-
pants gave written informed consent. All women living in
the UK and aged 16 years or older were eligible to join the
study. Registered supporters of the charity Breakthrough
Breast Cancer were invited, and other women joined ei-
ther by self-referral or by nomination from an existing
participant. Over 113,000 participants were recruited be-
tween 2003 and 2013. As a requirement of study entry, all
BGS participants completed a postal recruitment ques-
tionnaire, which included detailed questions about known
and possible breast cancer risk factors. Participants are
followed-up approximately every two and a half years,
using further postal questionnaires that update the re-
cruitment information and reports of cancer diagnoses.
Follow-up is based on time since recruitment; thus, at any
given time different participants are at different stages of
follow-up, because recruitment occurred over 10 years. At
present, up to two rounds of follow-up questionnaires
have been sent to participants, depending on when they
were recruited. Further details of the cohort can be found
elsewhere [10].
BGS participants were potentially eligible for the current
analyses if they joined the study before 1 April 2010,
and thus had reached at least their first follow-up
point (N = 111,344). Of these, 6,399 women were diag-
nosed with invasive or in situ breast cancer and 14
had a prophylactic bilateral mastectomy before they
joined the BGS, and therefore were excluded from the
analysis. This left 104,931 subjects who formed the
study cohort.
Variables
Incident invasive and in situ breast cancers were identi-
fied from participants’ reports in the follow-up question-
naires and spontaneous reports to the study centre, and
from flagging at the NHS Central Registers - virtually
complete registers of the populations of England and
Wales, and of Scotland, on which deaths and cancer reg-
istrations are ‘flagged’ and then reported to authorised
medical researchers. For a total of 99% (1,082 out of
1,094) of reported cases, the diagnosis was confirmed by
cancer registry data or pathology reports (95%) or from
the participant’s general practitioner (4%); the remaining
1% were assumed to be true cases because they reported
appropriate treatment for breast cancer.
The explanatory and confounding variables analysed
were from self-reported data on the recruitment ques-
tionnaire. The explanatory variables were age at the-
larche, age at menarche, age at regular periods, age
when reached adult height, the intervals between these
ages, and growth spurt in height between ages 7 and 11
years (as a proxy for peak growth). Age at regular pe-
riods was only analysed for women who indicated that
their periods had become regular naturally rather than
as a consequence of oral contraceptives or some other
cause. All ages were reported to the last completed year.
Information about height in childhood was collected as
self-reported height relative to other girls of the same
age, in five categories. Subjects were classed as having
had a growth spurt between ages 7 and 11 years if their
height compared with girls of a similar age increased by
at least one category from age 7 to 11.
The potential confounding variables analysed were age
at recruitment (years, continuous), menopausal status
(postmenopausal, premenopausal), family history of breast
cancer in a first-degree relative (yes, no), adult height
(centimetres, continuous), age at first full-term pregnancy
(≤24 years, 25 to 29 years, ≥30 years, nulliparous), and
hormone replacement therapy (HRT) use (yes, no). These
variables were selected as they are breast cancer risk fac-
tors and, in exploratory analyses, affected the relationship
between at least one of the explanatory variables and
breast cancer risk. Adjustments for ethnicity and socio-
economic status, (based on place of residence (Acorn
scores [11])), were also made, but these had no effect on
the results and have not been included in the results
presented.
Statistical analysis
The data were analysed using survival analysis methods.
Subjects contributed person-time from recruitment into
the BGS until the earliest of: end of follow-up period,
diagnosis of invasive or in situ breast cancer, death, emi-
gration from the UK or loss to follow-up. The follow-up
period was based on the date of the second follow-up
questionnaire for the 49,880 women who joined the
study before 1 July 2006, and on the date of the first
follow-up questionnaire for the remaining women. Par-
ticipants who were lost to questionnaire follow-up were
flagged with the NHS Central Registers, if they had
agreed to this. If flagged, they were then censored at
31 December 2010 because national cancer incidence
data are currently incomplete after that date; other-
wise, they were censored at loss to follow-up.
Cox regression models were fitted in Stata 10.1 (Stata-
Corp, College Station, Texas, USA) [12] with attained age
as the underlying time variable, invasive or in situ breast
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cancer diagnosis as the event of interest, and all other out-
comes censored. The validity of the proportional hazards
assumption was assessed for each model. The initial models
were unadjusted but accounted for age, because it was
the underlying time variable, and menopausal status, as
time at risk was stratified by menopausal status (pre- and
post-menopausal). Also analyses were conducted separately
for these two menopause categories as pre- and post-
menopausal breast cancer have been shown to have different
aetiologies to some extent [13]. Menopausal status was
based on recruitment questionnaire and subsequently
updated from follow-up questionnaires. The date at which a
participant became post-menopausal was determined by her
reported age at natural menopause or bilateral oophorec-
tomy, or if these were unknown (for example, because of
hysterectomy, or hormonal contraceptive or HRT use) at
age 50 or the age at which she was last known to be pre-
menopausal, whichever was later. Additional models were
fitted that additionally adjusted for family history of breast
cancer, adult height, age at first full-term pregnancy and
HRT use. These are the results described in the text unless
otherwise specified, since both the unadjusted and adjusted
findings were very similar. Missing data were not imputed.
Sensitivity analyses were performed by repeating the
analyses in various subgroups: women who were younger
than age 60 years at recruitment, because recall might be
better in these women; after exclusion of women who had
a younger first-degree relative in the BGS because of po-
tential correlation within pairs; and taking only invasive or
in situ breast cancers as the outcome of interest in turn.
Receptor status was known for too few women to allow
analyses to be split by this factor.
Results
Table 1 shows descriptive characteristics of the 104,931
BGS participants who formed the cohort analysed. The
subjects were aged 16 to 98 years at recruitment (mean =
46.7 years; median = 47 years), and the vast majority were
of white ethnicity (98.8%).
During follow-up (average follow-up = 4.05 years, total
person-years = 424,262), 1,094 (1.0%) women in the co-
hort were diagnosed with invasive (965; 88.2%) or in situ
(129; 11.8%) breast cancer, 20 (0.02%) had a prophylactic
bilateral mastectomy, 349 (0.3%) died, and 99,545
(94.9%) were followed to the end of their follow-up
period. Of the remaining 3,924 (3.7%), 3,240 (3.1%)
were followed to December 2010 by flagging, 423 (0.4)
were censored at emigration and 261 (0.3%) were lost
to follow-up.
Table 2 presents the risk of breast cancer by pubertal
factors. An earlier thelarche was associated with higher
breast cancer risk; women with a reported age at the-
larche ≤10 years had approximately 20% higher risk of
breast cancer than those who reported an age at
thelarche between 11 and 12 years (HR = 1.23 (95% CI =
1.02, 1.48)). Similarly, thelarche at age 13 years or older
was associated with a 20% lower risk of breast cancer
(0.80 (0.69, 0.93)). A lower risk of breast cancer was also
seen in women whose menarche (0.78 (0.62, 0.99)) or
regular periods (0.74 (0.59, 0.92)) onset at 15 years or
older compared with age 13 to 14 years, but onset at 12
years or younger was not associated with an increased
risk. Conversely, women who reached their adult height
at a younger age had an increased risk (1.25 (1.03, 1.52)),
but reaching it at an older age (≥17 years) was not
Table 1 Baseline characteristics of cohort participants
Variable Mean [SD] or N (%)
Age at recruitment, years 46.7 [13.4]
Average person-time, years 4.1 [1.7]
Adult height, cm 164.3 [6.6]
Menopausal status
Postmenopausal 44,373 (42.3)
Premenopausal 60,534 (57.7)
Never periods 24 (0.0)
Family history of breast cancer
No 89,069 (84.9)
Yes 15,862 (15.1)
Age at first full-term pregnancy, years
≤24 25,700 (24.5)
25 to 29 31,104 (29.6)
≥30 19,285 (18.4)
Parous; age not reported 166 (0.2)
Nulliparous 28,513 (27.2)
Parity missing 163 (0.2)
Ethnicity
White 103,655 (98.8)
Mixed white/non-white 585 (0.5)
Non-white 611 (0.6)
Missing 80 (0.1)
Socio-economic statusa
1 (Highest) 47,952 (45.7)
2 12,001 (11.4)
3 29,886 (28.5)
4 8,449 (8.0)
5 (Lowest) 6,042 (5.8)
Channel islands/isle of manb 497 (0.5)
Unclassified 104 (0.1)
Total 104,931 (100.0)
SD, Standard deviation.
aSocio-economic status was based on placed of residence (Acorn scores).
bResidence-based socio-economic status not classifiable.
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protective. Breast cancer risk was not significantly
associated with having a linear growth spurt between
ages 7 and 11.
Table 3 shows the risk of invasive or in situ breast
cancer by the duration between pubertal events. Breast
cancer risk increased as the time between thelarche and
menarche increased, but was only significant in those
whose menarche occurred at least two years after the
onset of thelarche (1.27 (1.04, 1.55)). Breast cancer risk
also increased as the time between menarche and regu-
lar periods decreased, but again was only significant
when the time between the two events was at least two
years (0.66 (0.50, 0.88)). Breast cancer risk was not
significantly associated with the time between thelarche
and onset of regular periods, or between menarche and
attaining adult height.
For premenopausal and postmenopausal breast cancer
analysed separately (Additional file 1: Tables S1 and S2)
and in sensitivity analyses (Additional file 1: Tables S3
and S4), the overall findings were similar to the main
results in terms of the effect sizes and general pattern of
results. Results for invasive and in situ breast cancers
were broadly similar with no significant differences.
Discussion
Increased breast cancer risk was associated with an earlier
thelarche, earlier menarche, earlier regular periods, a lon-
ger time between thelarche and menarche, or a shorter
Table 2 Risk of invasive or in situ breast cancer in relation to pubertal variables
Adjusted for attained age Multivariate-adjusteda
Pubertal variable N cases/person-years HR (95% CI) N cases/person-years HR (95% CI)
Age at thelarche, years
≤10 152/53,916 1.22 (1.02,1.47) * 151/53,308 1.23 (1.02, 1.48) *
11 to 12 445/17,5791 Referent 443/173,413 Referent
≥13 276/120,309 0.82 (0.71,0.96) * 269/118,581 0.80 (0.69, 0.93) **
HR for trend 0.82 (0.74, 0.90) *** 0.81 (0.73, 0.89) ***
Age at menarche, years
≤12 451/171,139 1.03 (0.90,1.17) 449/168,478 1.06 (0.93,1.21)
13 to 14 449/171,466 Referent 444/168,733 Referent
≥15 86/38,779 0.81 (0.64,1.02) 83/38,109 0.78 (0.62,0.99) *
HR for trend 0.92 (0.83, 1.01) 0.89 (0.81, 0.99) *
Age at regular periods, years
≤12 213/80,631 0.97 (0.81,1.15) 212/79,450 0.99 (0.83,1.18)
13 to 14 295/107,008 Referent 292/105,314 Referent
≥15 105/50,215 0.74 (0.59,0.93) ** 104/49,465 0.74 (0.59,0.92) **
Never had 73/26,114 1.15 (0.89,1.49) 73/25,581 1.16 (0.90,1.50)
regular periods
HR for trendb 0.90 (0.81, 1.00) 0.88 (0.79, 0.98) *
Age reached adult height, years
≤14 198/73,048 1.20 (0.99,1.45) 198/72,430 1.25 (1.03,1.52) *
15 to 16 212/100,038 Referent 208/98,651 Referent
≥17 148/69,134 1.06 (0.86,1.31) 148/67,894 1.07 (0.87,1.32)
HR for trend 0.93 (0.84, 1.04) 0.92 (0.82, 1.02)
Growth spurt between ages 7 and 11 yearsc
No 956/37,8071 Referent 947/372,171 Referent
Yes 100/34,784 1.15 (0.94,1.41) 98/34,259 1.12 (0.91,1.38)
CI ,Confidence interval; HR, Hazard ratio.
*P <0.05; **P <0.01; ***P <0.001.
aAdjusted for attained age, menopausal status, family history of breast cancer in a first-degree relative, adult height, age at first full-term pregnancy (with a term
for nulliparous women) and HRT status.
bTest for trend excludes those who had never had a regular period.
cSubjects were classed as having had a growth spurt between ages 7 and 11 years if their height compared with girls of a similar age increased by at least one
category from age 7 to 11.
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time between menarche and the onset of regular periods.
Findings were generally similar when premenopausal and
postmenopausal breast cancer were analysed separately
and in sensitivity analyses.
There is evidence that breast cancer aetiology com-
prises several pathways, some of which have their origins
early in life [14,15]. It has been postulated that a larger
number of undifferentiated cells in the breast might
increase breast cancer risk [14,15], because undifferenti-
ated cells appear to be more liable to undergo malignant
transformation than differentiated cells, based on epi-
demiological [14] and rat [16] studies. Another postu-
lated pathway relates to hormones, such as oestrogen,
that increase cell proliferation, thereby increasing the
chance of harmful mutations occurring during DNA
replication. These pathways suggest that the timing of
puberty could potentially affect breast cancer risk be-
cause the number of undifferentiated breast cells
increases rapidly during puberty [16] and it is a time of
substantial changes in the hormonal environment [17].
Thelarche marks the start of pubertal breast growth
after a period of relatively few changes during childhood
[16]. Our findings provided evidence that earlier the-
larche may be associated with a higher risk of breast
cancer. We can find no previous data on the effects of
age at thelarche on breast cancer risk [18]. There are
plausible biological mechanisms by which early thelarche
might increase risk. At puberty, breast ducts begin to
Table 3 Risk of invasive or in situ breast cancer in relation to duration between pubertal events
Adjusted for attained age Multivariate-adjusteda
Pubertal variable N cases/person-years HR (95% CI) N cases/person-years HR (95% CI)
Thelarche to menarche, years
<0 57/27,759 0.85 (0.64,1.13) 57/27,381 0.87 (0.65,1.15)
0 275/112,810 Referent 271/111,168 Referent
1 303/116,433 1.14 (0.97,1.34) 299/114,967 1.14 (0.96,1.34)
≥2 156/61,061 1.27 (1.05,1.55) * 155/60,301 1.27 (1.04,1.55) *
P for trend 1.14 (1.05, 1.23) ** 1.13 (1.05, 1.23) **
Thelarche to regular periods, years
<0 24/9,864 0.88 (0.57,1.36) 24/9,734 0.89 (0.58,1.38)
0 129/46,383 Referent 127/45,750 Referent
1 179/71,457 0.93 (0.74,1.16) 177/70,595 0.92 (0.73,1.15)
≥2 188/81,162 0.94 (0.75,1.18) 187/80,149 0.93 (0.74,1.16)
Never became 73/26,114 1.19 (0.89,1.59) 73/25,581 1.19 (0.89,1.58)
regular
P for trendb 0.99 (0.90, 1.09) 0.98 (0.89, 1.08)
Menarche to regular periods, years
0 379/134,744 Referent 376/132,702 Referent
1 180/71,866 0.88 (0.74,1.06) 178/70,749 0.87 (0.73,1.04)
≥2 54/31,244 0.67 (0.51,0.90) ** 54/30,778 0.66 (0.50,0.88) **
Never became 73/26,114 1.14 (0.89,1.47) 73/25,581 1.13 (0.88,1.46)
regular
P for trendb 0.84 (0.75, 0.95) ** 0.84 (0.74, 0.94) **
Menarche to adult height, years
<0 14/5,941 0.90 (0.52,1.56) 14/5,871 0.90 (0.52,1.57)
0 to 1 131/50,937 Referent 130/50,492 Referent
2-3 191/83,968 0.98 (0.79,1.23) 189/82,911 0.96 (0.77,1.21)
≥4 165/78,925 0.94 (0.75,1.19) 165/77,560 0.94 (0.75,1.19)
P for trend 0.98 (0.89, 1.09) 0.98 (0.88, 1.09)
CI, Confidence interval; HR, Hazard ratio.
*P <0.05; **P <0.01; *** P<0.001.
aAdjusted for attained age, menopausal status, family history of breast cancer in a first-degree relative, adult height, age at first full-term pregnancy (with a term
for nulliparous women) and HRT status.
bTest for trend excludes those who had never had a regular period.
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grow and divide, and the ends of the ducts form ter-
minal end buds [16]. The breast comprises predomin-
antly undifferentiated, proliferating cells until the first
full-term pregnancy and lactation, at which point a large
proportion of breast cells differentiate fully [16]. There-
fore, an earlier thelarche might suggest a longer time
during which the breast comprises a high number of un-
differentiated cells and thus has a higher risk of harmful
mutations developing [14,15], particularly among women
who have the same age at first full-term pregnancy.
Menarche also marks a key stage of breast develop-
ment. At menarche, the rate at which breast ducts grow
and divide increases [19]. Early menarche is a well-
established breast cancer risk factor [6,20,21] with our
estimated HRs broadly consistent with those seen in the
literature [6]. The effect of early menarche might be due
to oestrogens, because they increase breast cell prolifera-
tion [22] and have been related to breast cancer risk
[23], to a larger number of undifferentiated cells due to
increased mammary gland size after menarche, and/or
to a potentially longer time when the breast is largely
undifferentiated among women with a similar age at first
pregnancy.
A longer duration from thelarche to menarche also
appeared to increase breast cancer risk independently of
the effect of age at thelarche in regression analyses when
age at thelarche was included as a potential confounder.
This does not seem to have been investigated previously.
However, the period between thelarche and menarche is
when breast duct development largely happens, so if
cells are more susceptible when in the ductal growth
phase, one might expect such an association with dur-
ation from thelarche to menarche. In the context of
radiation-induced breast cancer, at least, there is clear
evidence that the breast is more susceptible to a carcino-
genic exposure around the time of puberty than at other
times [24].
Some [7,8], but not all [25], studies have found a
higher risk of breast cancer among women whose men-
ses became regular soon after menarche compared with
those whose menses took longer to regulate or never be-
came regular. We found evidence to support this. It has
been suggested that women who have irregular cycles
have a reduced breast cancer risk because levels of ovar-
ian hormones are highest during the luteal phase of the
menstrual cycle and women with irregular cycles would
spend relatively less time in this phase than women who
have regular cycles [7]. This would suggest that age at
regular cycles would be associated with breast cancer
risk, not just time to regular cycles, which was the case
in our study in most, but not all, analyses.
Existing evidence suggests that rapid growth in child-
hood and adolescence may increase breast cancer risk
[26,27]. In the BGS, we did not find this in analyses in
which we estimated height velocity between ages 7 and
11 years by comparing categories of relative height at
these ages. Although these were comparative data based
on recall, some BGS participants (N = 199) reported
their absolute height at these ages because they or their
parents had kept records. Based on these recorded data,
the average increase in height from age 7 to 11 was 26.8
cm in the growth spurt group and 23.4 cm among par-
ticipants who were not classed as having had a growth
spurt (P <0.01 for difference), suggesting that our growth
spurt measure was a reasonable proxy.
It is also of interest whether the timing of the growth
spurt affects breast cancer risk. The age at peak growth
is one year earlier than menarche on average [28] and
was associated with increased breast cancer risk in a
large Danish study [20]. Age at which adult height was
reached is correlated with age at peak growth [29,30]
and, unlike age at peak growth, it can be ascertained by
recall. Generally, studies have found that older age at
attained height, and thus presumptively older age at
peak growth, is associated with a lower breast cancer
risk [29,31], but no such association was present in the
Nurses’ Health Study II [30]. Our data gave limited sup-
port: although no association was found in participants
overall, there was an association among women aged 60
years or younger at recruitment, whose recall might be
better.
The timing of pubertal events is likely to be correlated
to some extent, which may partly explain our findings
and the fact that many of the effect sizes were similar
Table 4 Correlations between timing of pubertal variables
Thelarche Menarche Regular
periods
Reached adult
height
Thelarche to
menarche
Thelarche to
regular periods
Menarche to
regular periods
Menarche 0.02
Regular periods 0.02 0.58
Reached adult height 0.00 0.34 0.22
Thelarche to menarche 0.00 −0.01 0.81 0.03
Thelarche to regular periods −1.00 −0.02 −0.01 −0.00 −0.00
Menarche to regular periods −1.00 −0.02 −0.01 −0.00 0.01 1.00
Menarche to adult height −0.01 −0.36 −0.19 0.75 0.03 0.01 0.01
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across pubertal events. However, Table 4 shows that the
correlation between event timing was low in most in-
stances. Interestingly, the duration between thelarche
and menarche was not correlated with age at thelarche
or age at menarche, but was highly correlated with age
at regular periods. Likewise, age at thelarche was highly
correlated with time between menarche and regular
periods, but not with age at menarche or age at regular
periods. These high correlations suggest that these risk
factors may be acting through the same pathway as each
other or one may be a marker for the other.
These analyses included comprehensive adjustment for
potential confounders. While benign breast disease is an
established risk factor for breast cancer, we did not ad-
just for it as it is unlikely to be a confounder of the rela-
tionship between puberty variables and breast cancer. It
is possible that benign breast disease is on the same
causal pathway and is a mediator of the relationship be-
tween pubertal variables and breast cancer risk, though
evidence linking pubertal factors to benign breast disease
is lacking.
The pubertal variables that we analysed were reported
retrospectively; therefore their accuracy should be con-
sidered. Whereas menarche is a well-defined single event
that women can recall with reasonable accuracy (for
example, 90% accurately recalled the age within a year in
one study [2]), the onset of breast development, regular
menses and peak growth cannot be ascertained by a sin-
gle event and, hence, recall is likely to be less accurate.
There is some evidence of this inaccuracy for regular
menses [2,32], but the validity of recalled age at the-
larche does not appear to have been studied previously
and we had to rely on proxies for age at peak growth.
However, the timing of pubertal stages was reported at
baseline before breast cancer diagnosis and so it is un-
likely that recall of the pubertal stages would be biased
with respect to a subsequent breast cancer diagnosis.
Thus, the likely effect of inaccurate recall would have
been to attenuate any true associations.
Another limitation of the present analyses is that the
average follow-up was only four years. Despite this,
more than 1,000 breast cancers had occurred due to the
size of the cohort. In addition to the large sample size,
the other strengths of this study were its prospective na-
ture, and that it examined several potential breast cancer
risk factors for which there has been no or little existing
research.
While the only inclusion criteria for women to join
the BGS were that they must be aged at least 16 years
and living in the UK, there are indications that the study
participants are on average a somewhat high-risk popu-
lation - they tend to be of higher socioeconomic status
and more often to have a family history of breast cancer
than the UK general population [10]. There seems no
reason, however, why this should have affected the asso-
ciations, as opposed to the distribution of risk factors,
reported here.
Conclusions
In conclusion, the novel findings of this study are that
earlier thelarche and a longer time between thelarche
and menarche might increase breast cancer risk, as well
as the already-investigated effects of early menarche,
regular periods and the time between the two. This sug-
gests that breast duct development may be a period of
raised susceptibility to breast carcinogenesis, and that
the association between puberty and breast cancer is com-
plex and not best represented by a single event. Further
research on the effects of pubertal stages other than age at
menarche is needed to elucidate these relationships.
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